Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMB-2301
- Development stage
- Preclinical
- Lead developer
- Guangzhou Jiayue Pharmaceutical Technology
- Modality
- Small Molecules
01
Overview
JMB-2301 is a preclinical-stage therapeutic candidate developed by Guangzhou Jiayue Pharmaceutical Technology (also known as Jeyou Pharma). As of 2024, the asset is in the early discovery or preclinical phase, with its specific biological target and therapeutic indication not yet publicly disclosed in the company's pipeline. Jeyou Pharma's research and development efforts are primarily concentrated on innovative small molecule and biologic therapies for chronic kidney disease (CKD), oncology, and inflammatory disorders. JMB-2301 represents one of the company's early-stage pipeline assets alongside other programs targeting V2R, NHE3, and KRAS.
Beyond the preview
Go deeper on JMB-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMB-2301.